Paul A Friedman sold $154k of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 280 shares at an average of $551.24, traded Jan 9, 2026, filed Jan 13, 2026.
Score components
- +15RoleDirector
- +11Trade size$154k at market
- 0Share of holdings soldSold 0.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-001981, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 9, 2026 | MOption exercise Common Stock10b5-1 | +280 | $15.80 | $4,424 | 187,444 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -280 | $551.24 | $154k | 187,164 | Jan 13, 2026 |
| Jan 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -280 | $0.00 | $0 | 0 | Jan 13, 2026 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $505k 1,183 shares | -11% | |
| 27Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $449k 910 shares | -9% | |
| 44Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $319k 647 shares | -0% | |
| 62Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $777k 1,577 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.